A roundup of bio/pharmaceutical partnering news from Eli Lilly and Company/Haya Therapeutics, Novartis/Lindy Biosciences and Pfizer/Flagship Pioneering/Quotient Therapeutics. 

* Lilly, Haya Theraepeutics in $1-Bn Deal for RNA-Based Drug Discovery for Obesity Drugs 
* Novartis, Lindy Biosciences in $954-M Pact for Self-Administered Injectable Drug Delivery 
* Pfizer, Flagship Pioneering, Quotient Therapeutics Form Strategic Partnership for Cardio, Renal Diseases  

---

Lilly, Haya Theraepeutics in $1-Bn Deal for RNA-Based Drug Discovery for Obesity Drugs 
Eli Lilly and Company and Haya Therapeutics, a Lausanne, Switzerland-based bio/pharma company focused on developing RNA-based therapeutics, have entered a multi-year agreement to apply Haya’s RNA-guided regulatory genome platform to support Lilly’s preclinical drug discovery efforts in obesity and related metabolic conditions, in a deal worth up to $1 billion.  

Haya is a precision medicines company developing programmable therapeutics targeting regulatory RNAs derived from the dark genome, a cell information processing unit, to reprogram pathological cell states for a broad range of diseases, including cardiovascular and metabolic diseases and cancer. The company is using its technology platforms to gain insights into the biology of disease cell states and the long non-coding RNAs (lncRNAs) that regulate them. HAYA’s lead therapeutic candidate is HTX-001, in development for the treatment of heart failure. HAYA is also developing a pipeline of lncRNA-targeting precision therapies for the cell-specific treatment of diseases in other tissues. 

Under the agreement, Haya will receive an upfront payment, including an equity investment, and is eligible to receive up to an aggregate $1 billion in preclinical, clinical and commercial milestone payments as well as royalties on product sales. 

Source: Haya Therapeutics 

---

Novartis, Lindy Biosciences in $954-M Pact for Self-Administered Injectable Drug Delivery 
Novartis and Lindy Biosciences, a Morrisville, North Carolina-based drug-delivery company, have entered a multi-target exclusive global licensing agreement and strategic collaboration, in a deal worth up to $954 million ($20 million upfront and $934 million in milestone payments). 

The collaboration will focus on transitioning select innovative medicines from the Novartis portfolio to subcutaneous injections using Lindy Biosciences’ microglassification suspension technology. The technology allows for the delivery of high concentrations of biologics to increases the maximum dose that can be administered in a single subcutaneous injection, according to information from Lindy Bioscienes.  

Source: Lindy Biosciences 

---

Pfizer, Flagship Pioneering, Quotient Therapeutics Form Strategic Partnership for Cardio, Renal Diseases 
Pfizer, Flagship Pioneering, a private equity firm that funds new bio/pharmaceutical companies (bioplatform companies), and Quotient Therapeutics, a Nottingham, UK-based bioplatform company of Flagship Pioneering, have entered a strategic partnership under which the companies will analyze somatic mutations that occur in diseased patient tissue to inform the discovery and development of therapies for cardiovascular and renal diseases. 

Pioneering Medicines, Flagship’s in-house drug-discovery and development unit, is responsible for leading the strategic partnership with Pfizer, including driving the exploration process for potential drug development programs built on Flagship’s bioplatforms and modalities. The Quotient agreement is the most recent program initiated under Flagship’s strategic partnership with Pfizer that was announced in July 2023. 

Source: Flagship Pioneering